Emerging understanding of the protein corona at the nano-bio interfaces

[1]  Morteza Mahmoudi,et al.  Biological Identity of Nanoparticles In Vivo: Clinical Implications of the Protein Corona. , 2017, Trends in biotechnology.

[2]  G. El Fakhri,et al.  Renal Clearable Organic Nanocarriers for Bioimaging and Drug Delivery , 2016, Advanced materials.

[3]  M. Mahmoudi,et al.  Bypassing Protein Corona Issue on Active Targeting: Zwitterionic Coatings Dictate Specific Interactions of Targeting Moieties and Cell Receptors. , 2016, ACS applied materials & interfaces.

[4]  Katharina Landfester,et al.  Controlling the Stealth Effect of Nanocarriers through Understanding the Protein Corona. , 2016, Angewandte Chemie.

[5]  Raehyun Kim,et al.  The importance of selecting a proper biological milieu for protein corona analysis in vitro: Human plasma versus human serum. , 2016, The international journal of biochemistry & cell biology.

[6]  Luca Digiacomo,et al.  Personalized liposome-protein corona in the blood of breast, gastric and pancreatic cancer patients. , 2016, The international journal of biochemistry & cell biology.

[7]  Alaaldin M. Alkilany,et al.  Protein corona: Opportunities and challenges. , 2016, The international journal of biochemistry & cell biology.

[8]  Alaaldin M. Alkilany,et al.  Misinterpretation in Nanotoxicology: A Personal Perspective. , 2016, Chemical research in toxicology.

[9]  Heidi Ledford.  Bankruptcy filing worries developers of nanoparticle cancer drugs , 2016, Nature.

[10]  Sung Tae Kim,et al.  Regulation of Macrophage Recognition through the Interplay of Nanoparticle Surface Functionality and Protein Corona. , 2016, ACS nano.

[11]  Katharina Landfester,et al.  Protein adsorption is required for stealth effect of poly(ethylene glycol)- and poly(phosphoester)-coated nanocarriers. , 2016, Nature nanotechnology.

[12]  M. Mahmoudi.  Protein corona: The golden gate to clinical applications of nanoparticles. , 2016, The international journal of biochemistry & cell biology.

[13]  K. Landfester,et al.  Protein source and choice of anticoagulant decisively affect nanoparticle protein corona and cellular uptake. , 2016, Nanoscale.

[14]  Ophir Vermesh,et al.  Targeted superparamagnetic iron oxide nanoparticles for early detection of cancer: Possibilities and challenges. , 2016, Nanomedicine : nanotechnology, biology, and medicine.

[15]  V. Rotello,et al.  Using the Power of Organic Synthesis for Engineering the Interactions of Nanoparticles with Biological Systems. , 2016, Nano today.

[16]  M. Mahmoudi,et al.  Impact of protein pre-coating on the protein corona composition and nanoparticle cellular uptake. , 2016, Biomaterials.

[17]  Francesco Salvatore,et al.  The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery. , 2016, Nanomedicine.

[18]  J. Reynolds,et al.  Nanomedicine applied to translational oncology: A future perspective on cancer treatment. , 2016, Nanomedicine : nanotechnology, biology, and medicine.

[19]  Ashley M. Laughney,et al.  Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle , 2015, Science Translational Medicine.

[20]  Chor Yong Tay,et al.  Understanding and exploiting nanoparticles' intimacy with the blood vessel and blood. , 2015, Chemical Society reviews.

[21]  S. Hou,et al.  The Interplay of Size and Surface Functionality on the Cellular Uptake of Sub-10 nm Gold Nanoparticles. , 2015, ACS nano.

[22]  G. Caracciolo,et al.  Stealth effect of biomolecular corona on nanoparticle uptake by immune cells. , 2015, Langmuir : the ACS journal of surfaces and colloids.

[23]  Morteza Mahmoudi,et al.  Nanotoxicology: advances and pitfalls in research methodology. , 2015, Nanomedicine.

[24]  Vincent M Rotello,et al.  Acylsulfonamide-Functionalized Zwitterionic Gold Nanoparticles for Enhanced Cellular Uptake at Tumor pH. , 2015, Angewandte Chemie.

[25]  M. Mahmoudi,et al.  Personalized disease-specific protein corona influences the therapeutic impact of graphene oxide. , 2015, Nanoscale.

[26]  Christoffer Åberg,et al.  Mapping protein binding sites on the biomolecular corona of nanoparticles. , 2015, Nature nanotechnology.

[27]  M. Mahmoudi,et al.  Monoclonal antibody conjugated magnetic nanoparticles could target MUC-1-positive cells in vitro but not in vivo. , 2015, Contrast media & molecular imaging.

[28]  Giulio Caracciolo,et al.  Liposome-protein corona in a physiological environment: challenges and opportunities for targeted delivery of nanomedicines. , 2015, Nanomedicine : nanotechnology, biology, and medicine.

[29]  Warren C W Chan,et al.  Nanoparticle-blood interactions: the implications on solid tumour targeting. , 2015, Chemical communications.

[30]  H. Santos,et al.  Functionalization of alkyne-terminated thermally hydrocarbonized porous silicon nanoparticles with targeting peptides and antifouling polymers: effect on the human plasma protein adsorption. , 2015, ACS applied materials & interfaces.

[31]  Giulio Caracciolo,et al.  Size and charge of nanoparticles following incubation with human plasma of healthy and pancreatic cancer patients. , 2014, Colloids and surfaces. B, Biointerfaces.

[32]  K. Landfester,et al.  Protein corona change the drug release profile of nanocarriers: the "overlooked" factor at the nanobio interface. , 2014, Colloids and surfaces. B, Biointerfaces.

[33]  Wolfgang J. Parak,et al.  Back to Basics: Exploiting the Innate Physico‐chemical Characteristics of Nanomaterials for Biomedical Applications , 2014 .

[34]  V. Rotello,et al.  The Role of Surface Functionality in Nanoparticle Exocytosis , 2014, Advanced healthcare materials.

[35]  Morteza Mahmoudi,et al.  Personalized protein coronas: a "key" factor at the nanobiointerface. , 2014, Biomaterials science.

[36]  Leone Spiccia,et al.  Zwitterionic-coated "stealth" nanoparticles for biomedical applications: recent advances in countering biomolecular corona formation and uptake by the mononuclear phagocyte system. , 2014, Small.

[37]  Bo Yan,et al.  Fabrication of Corona-Free Nanoparticles with Tunable Hydrophobicity , 2014, ACS nano.

[38]  Andrew Emili,et al.  Secreted biomolecules alter the biological identity and cellular interactions of nanoparticles. , 2014, ACS nano.

[39]  Morteza Mahmoudi,et al.  Variation of protein corona composition of gold nanoparticles following plasmonic heating. , 2014, Nano letters.

[40]  James Chen Yong Kah,et al.  Optimizing the properties of the protein corona surrounding nanoparticles for tuning payload release. , 2013, ACS nano.

[41]  Stefan Tenzer,et al.  Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. , 2013, Nature nanotechnology.

[42]  Say Chye Joachim Loo,et al.  Titanium dioxide nanomaterials cause endothelial cell leakiness by disrupting the homophilic interaction of VE–cadherin , 2013, Nature Communications.

[43]  M. Mahmoudi,et al.  Graphene: promises, facts, opportunities, and challenges in nanomedicine. , 2013, Chemical reviews.

[44]  Jianjun Cheng,et al.  Protein corona significantly reduces active targeting yield. , 2013, Chemical communications.

[45]  H. Mattoussi,et al.  Growth of highly fluorescent polyethylene glycol- and zwitterion-functionalized gold nanoclusters. , 2013, ACS nano.

[46]  M. Mahmoudi,et al.  Significance of cell "observer" and protein source in nanobiosciences. , 2013, Journal of colloid and interface science.

[47]  Philip M. Kelly,et al.  Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. , 2013, Nature nanotechnology.

[48]  Marco P Monopoli,et al.  Biomolecular coronas provide the biological identity of nanosized materials. , 2012, Nature nanotechnology.

[49]  James E Bear,et al.  PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. , 2012, Nano letters.

[50]  Morteza Mahmoudi,et al.  Cell "vision": complementary factor of protein corona in nanotoxicology. , 2012, Nanoscale.

[51]  Wen-Chung Yu,et al.  Plasma Protein Characteristics of Long-Term Hemodialysis Survivors , 2012, PloS one.

[52]  Subinoy Rana,et al.  Surface functionalization of nanoparticles for nanomedicine. , 2012, Chemical Society reviews.

[53]  Andrew Emili,et al.  Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. , 2012, Journal of the American Chemical Society.

[54]  Urs O. Häfeli,et al.  Crucial Ignored Parameters on Nanotoxicology: The Importance of Toxicity Assay Modifications and “Cell Vision” , 2012, PloS one.

[55]  V. Rotello,et al.  Modulating Pharmacokinetics, Tumor Uptake and Biodistribution by Engineered Nanoparticles , 2011, PloS one.

[56]  Morteza Mahmoudi,et al.  Toxicity evaluations of superparamagnetic iron oxide nanoparticles: cell "vision" versus physicochemical properties of nanoparticles. , 2011, ACS nano.

[57]  M. Mahmoudi,et al.  Protein-nanoparticle interactions: opportunities and challenges. , 2011, Chemical reviews.

[58]  Yi Zhu,et al.  Chinese Anti鄄 Cancer a Ssociation , 2022 .

[59]  Jacob Kennedy,et al.  Plasma Proteome Profiles Associated with Inflammation, Angiogenesis, and Cancer , 2011, PloS one.

[60]  A. Gabizon,et al.  Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients , 2011, Cancer Chemotherapy and Pharmacology.

[61]  K. Jain,et al.  Advances in the field of nanooncology , 2010, BMC medicine.

[62]  Iseult Lynch,et al.  What the cell "sees" in bionanoscience. , 2010, Journal of the American Chemical Society.

[63]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[64]  Francesco Stellacci,et al.  Effect of surface properties on nanoparticle-cell interactions. , 2010, Small.

[65]  S. Everse,et al.  A loop in the N‐lobe of human serum transferrin is critical for binding to the transferrin receptor as revealed by mutagenesis, isothermal titration calorimetry, and epitope mapping , 2009, Journal of molecular recognition : JMR.

[66]  T. Xia,et al.  Understanding biophysicochemical interactions at the nano-bio interface. , 2009, Nature materials.

[67]  G. Chrousos.  Stress and disorders of the stress system , 2009, Nature Reviews Endocrinology.

[68]  Shaoyi Jiang,et al.  Novel zwitterionic-polymer-coated silica nanoparticles. , 2009, Langmuir : the ACS journal of surfaces and colloids.

[69]  Vincent M. Rotello,et al.  Applications of Nanoparticles in Biology , 2008 .

[70]  S. Acharya,et al.  Rare inherited disorders of fibrinogen , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[71]  A. Ullrich,et al.  Paul Ehrlich's magic bullet concept: 100 years of progress , 2008, Nature Reviews Cancer.

[72]  Kinam Park,et al.  Release of hydrophobic molecules from polymer micelles into cell membranes revealed by Förster resonance energy transfer imaging , 2008, Proceedings of the National Academy of Sciences.

[73]  S. Hanash,et al.  Mining the plasma proteome for cancer biomarkers , 2008, Nature.

[74]  P. Low,et al.  Fast release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo forster resonance energy transfer imaging. , 2008, Langmuir : the ACS journal of surfaces and colloids.

[75]  A. Blom,et al.  C4b-binding Protein and Factor H Compensate for the Loss of Membrane-bound Complement Inhibitors to Protect Apoptotic Cells against Excessive Complement Attack* , 2007, Journal of Biological Chemistry.

[76]  P. Couvreur,et al.  Analysis of plasma protein adsorption onto PEGylated nanoparticles by complementary methods: 2‐DE, CE and Protein Lab‐on‐chip® system , 2007, Electrophoresis.

[77]  J. Kreuter,et al.  Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[78]  S. Béni,et al.  Cyclodextrin/imatinib complexation: binding mode and charge dependent stabilities. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[79]  D. Allsop,et al.  Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[80]  R. Cardone,et al.  The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis , 2005, Nature Reviews Cancer.

[81]  D. Jaillard,et al.  Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: synthesis, physicochemical characterization, and in vitro experiments. , 2005, Bioconjugate chemistry.

[82]  R. Nelson,et al.  Investigating diversity in human plasma proteins. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[83]  Vincent M Rotello,et al.  Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. , 2004, Bioconjugate chemistry.

[84]  Thomas Walz,et al.  Structure of the Human Transferrin Receptor-Transferrin Complex , 2004, Cell.

[85]  N. Anderson,et al.  The Human Plasma Proteome , 2002, Molecular & Cellular Proteomics.

[86]  A. Blom,et al.  Vitamin K-Dependent Protein S Localizing Complement Regulator C4b-Binding Protein to the Surface of Apoptotic Cells1 , 2002, The Journal of Immunology.

[87]  B. Hedblad,et al.  Effects of Cholesterol and Inflammation-Sensitive Plasma Proteins on Incidence of Myocardial Infarction and Stroke in Men , 2002, Circulation.

[88]  B. Snel,et al.  Comparative assessment of large-scale data sets of protein–protein interactions , 2002, Nature.

[89]  S. J. Darnton,et al.  A primary tumour of the oesophagus with both melanocytic and schwannian differentiation. Melanocytic schwannoma or malignant melanoma? , 2002, Journal of clinical pathology.

[90]  I. H. Gibson.  An organ donor memorial. , 2002, Journal of clinical pathology.

[91]  R. Müller,et al.  'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. , 2000, Colloids and surfaces. B, Biointerfaces.

[92]  M. Grunze,et al.  MOLECULAR CONFORMATION AND SOLVATION OF OLIGO(ETHYLENE GLYCOL)-TERMINATED SELF-ASSEMBLED MONOLAYERS AND THEIR RESISTANCE TO PROTEIN ADSORPTION , 1997 .

[93]  Rakesh K. Jain,et al.  Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation , 1997, Nature Medicine.

[94]  A. Aderem,et al.  Molecular definition of distinct cytoskeletal structures involved in complement- and Fc receptor-mediated phagocytosis in macrophages , 1996, The Journal of experimental medicine.

[95]  R. Chang,et al.  A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist. , 1994, Journal of medicinal chemistry.

[96]  T. Springer,et al.  The major Fc receptor in blood has a phosphatidylinositol anchor and is deficient in paroxysmal nocturnal haemoglobinuria , 1988, Nature.

[97]  D. Dewhirst.  Newton's "claw", not paw! , 1988, Nature.

[98]  T. Merimee,et al.  Nonenzymatic Glycosylation of Serum and Plasma Proteins , 1982, Diabetes.

[99]  Z. Ruggeri,et al.  Variant von Willebrand's disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. , 1980, The Journal of clinical investigation.

[100]  H. Salt.  Plasma and Serum Proteins in Chronic Rheumatic Diseases , 1951, Annals of the rheumatic diseases.